Pediatric psoriasis treated with apremilast

BSA: body surface area INTRODUCTION Psoriasis is a cutaneous, chronic inflammatory disorder that affects approximately 3.1% of US adults younger than 60 years and up to 2.1% of children worldwide. Chronic plaque psoriasis is generally the most common type of childhood psoriasis (accounting for 74% of cases in one study), followed by guttate psoriasis (9.7%-28.9%), which is often triggered by streptococcal infection. Standardized guidelines for treating childhood psoriasis are lacking, and there are only limited evidence-based data and approved treatments. Case reports, therefore, can be an important source of guidance for clinicians. This case report discusses encouraging outcomes obtained with apremilast in an adolescent patient.